Renuvion is the only product cleared by the FDA to improve the appearance of lax (loose) skin on the neck and submental (chin) region. It has also recently been cleared for specific dermatological procedures for the treatment of moderate to severe lines and wrinkles, limited to patients with Fitzpatrick I, II or III skin types. These clearances highlight the safety and effectiveness of Renuvion’s technology.

To date, hundreds of physicians across the United States use Renuvion in their practices. For a list, by state, of physicians using the device, visit: https://renuvionfinder.com.

For more information, visit Renuvion.com.

About Apyx Medical Corporation:

Apyx Medical Corporation is a leading energy technology company with a passion for improving people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative helium plasma technology, Apyx is uniquely focused on bringing transformative solutions to the physicians and patients it serves. The Company’s Helium Plasma technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgery market. Renuvion® offers surgeons and physicians a unique ability to deliver controlled heat to tissue to achieve desired results. The J-Plasma® system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The company also leverages its deep expertise and decades of unique waveform experience through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For more information about the company and its products, please visit the Apyx Medical Corporation website at www.ApyxMedical.com.

Caution Regarding Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, it cannot guarantee that its expectations will be achieved.

All statements other than statements of historical facts are statements that could be considered forward-looking statements, including, but not limited to, any statement regarding the potential impact of the COVID-19 pandemic and the actions of governments, businesses and individuals in response to the situation; projections of net revenues, margins, expenses, net earnings, net earnings per share or other financial items; projections or assumptions regarding the Company’s eventual receipt of any regulatory approvals from any governmental agency or instrument, including but not limited to the United States Food and Drug Administration, chain disruptions supply shortages, component shortages, manufacturing disruptions or logistical issues; or macroeconomic or geopolitical matters and the impact of such matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that could cause the Company’s actual results to differ materially and which could affect the Company and the statements contained in this release include, but are not limited to, risks, uncertainties and assumptions. related to the regulatory environment to which the Company is subject, including the Company’s ability to obtain the required approvals for its products from the United States Food and Drug Administration and other governmental and regulatory bodies, both at the national and international; the impact of the FDA’s recent safety communication on our business and operations; factors relating to the effects of the COVID-19 pandemic; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes and effects of the geopolitical environment; liabilities and costs the Company may incur as a result of pending or threatened litigation, claims, disputes or investigations; and other risks described in the company’s annual report on Form 10-K for the year ended December 31, 2021 and other documents filed by the Company with the Securities and Exchange Commission. For the forward-looking statements contained in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company undertakes no obligation to update or supplement the forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Jane Sparango
Coterie Media on behalf of Apyx Medical Corporation
[email protected]

Investor Relations:

ICR Westwicke on behalf of Apyx Medical Corporation
Mike PiccininoCFA
investor[email protected]

SOURCE Renuvion

Comments are closed.